Jing Y - Search Results

1

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.

Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ, Zhuang G. Zhang Z, et al. Among authors: jing y. Theranostics. 2016 Jan 1;6(2):219-30. doi: 10.7150/thno.13178. eCollection 2016. Theranostics. 2016. PMID: 26877780 Free PMC article.

2

Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma.

Jia D, Jing Y, Zhang Z, Liu L, Ding J, Zhao F, Ge C, Wang Q, Chen T, Yao M, Li J, Gu J, He X. Jia D, et al. Among authors: jing y. Cell Res. 2014 Feb;24(2):204-17. doi: 10.1038/cr.2013.158. Epub 2013 Dec 3. Cell Res. 2014. PMID: 24296779 Free PMC article.

3

SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.

Jing Y, Jia D, Wong CM, Ng IO, Zhang Z, Liu L, Wang Q, Zhao F, Li J, Yao M, Wu X, He X. Jing Y, et al. Mol Oncol. 2014 Mar;8(2):366-77. doi: 10.1016/j.molonc.2013.12.003. Epub 2013 Dec 18. Mol Oncol. 2014. PMID: 24388360 Free PMC article.

4

Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex.

Jia D, Dong R, Jing Y, Xu D, Wang Q, Chen L, Li Q, Huang Y, Zhang Y, Zhang Z, Liu L, Zheng S, Xia Q, Wang H, Dong K, He X. Jia D, et al. Among authors: jing y. Hepatology. 2014 Nov;60(5):1686-96. doi: 10.1002/hep.27243. Epub 2014 Sep 19. Hepatology. 2014. PMID: 24912477

5

Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit.

Zhang Z, Zhang S, Ma P, Jing Y, Peng H, Gao WQ, Zhuang G. Zhang Z, et al. Among authors: jing y. Carcinogenesis. 2015 Sep;36(9):937-45. doi: 10.1093/carcin/bgv085. Epub 2015 Jun 12. Carcinogenesis. 2015. PMID: 26071398

6

Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.

Zhang S, Jing Y, Zhang M, Zhang Z, Ma P, Peng H, Shi K, Gao WQ, Zhuang G. Zhang S, et al. Among authors: jing y. Sci Rep. 2015 Nov 4;5:16066. doi: 10.1038/srep16066. Sci Rep. 2015. PMID: 26530441 Free PMC article.

7

Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.

Jing Y, Zhang Z, Ma P, An S, Shen Y, Zhu L, Zhuang G. Jing Y, et al. Oncotarget. 2016 Jan 19;7(3):2545-54. doi: 10.18632/oncotarget.6309. Oncotarget. 2016. PMID: 26575423 Free PMC article.

8

Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.

Ma P, Fu Y, Chen M, Jing Y, Wu J, Li K, Shen Y, Gao JX, Wang M, Zhao X, Zhuang G. Ma P, et al. Among authors: jing y. Theranostics. 2016 May 24;6(8):1232-43. doi: 10.7150/thno.14409. eCollection 2016. Theranostics. 2016. PMID: 27279914 Free PMC article.

9

A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.

Yin X, Wang X, Shen B, Jing Y, Li Q, Cai MC, Gu Z, Yang Q, Zhang Z, Liu J, Li H, Di W, Zhuang G. Yin X, et al. Among authors: jing y. Sci Rep. 2016 Aug 8;6:31079. doi: 10.1038/srep31079. Sci Rep. 2016. PMID: 27498762 Free PMC article.

10

Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.

Zhang Z, Peng H, Wang X, Yin X, Ma P, Jing Y, Cai MC, Liu J, Zhang M, Zhang S, Shi K, Gao WQ, Di W, Zhuang G. Zhang Z, et al. Among authors: jing y. Mol Cancer Ther. 2017 Sep;16(9):1739-1750. doi: 10.1158/1535-7163.MCT-17-0078. Epub 2017 Jun 1. Mol Cancer Ther. 2017. PMID: 28572168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,320 results

Search Page

Filters